[{"id":"fccbea54-6a5c-4b22-a431-9551c858f22a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03841110","created_at":"2021-10-25T16:56:27.673Z","updated_at":"2024-07-02T16:35:49.255Z","phase":"Phase 1","brief_title":"FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03841110","lead_sponsor":"Fate Therapeutics","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • FT500"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 02/15/2019","start_date":" 02/15/2019","primary_txt":" Primary completion: 11/15/2022","primary_completion_date":" 11/15/2022","study_txt":" Completion: 11/15/2022","study_completion_date":" 11/15/2022","last_update_posted":"2023-05-01"}]